Research Grade Trontinemab (DHC12508)
- CAS No.
- 2568868-35-7
- Chemical Name:
- Research Grade Trontinemab (DHC12508)
- Synonyms
- Trontinemab;Research Grade Trontinemab;Research Grade Trontinemab (DHC12508)
- CBNumber:
- CB112402174
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | N0GBZ1GWC2 |
Research Grade Trontinemab (DHC12508) price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0377109 | Trontinemab 99.93% | 2568868-35-7 | 1mg | $812 | 2026-06-04 | Buy |
| ChemScene | CS-0377109 | Trontinemab 99.93% | 2568868-35-7 | 5mg | $2112 | 2026-06-04 | Buy |
| ChemScene | CS-0377109 | Trontinemab 99.93% | 2568868-35-7 | 10mg | $3169 | 2026-06-04 | Buy |
| ChemScene | CS-0377109 | Trontinemab 99.93% | 2568868-35-7 | 25mg | $5254 | 2026-06-04 | Buy |
| aablocks | AA02AN7K | Trontinemab >98% | 2568868-35-7 | 1mg | $869 | 2026-06-02 | Buy |
Research Grade Trontinemab (DHC12508) Chemical Properties, Uses, Production
Uses
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1[1][2][3][4].
in vivo
Trontinemab (20 μg/mL) binding to TFR induces first infusion reaction (FIRs) and stimulation of cytokine release via Fc-mediated effector functions in FcgR-humanized mice[3].
References
[1] Neau M, et al. Monoclonal Antibody Therapy in Alzheimer's Disease. Pharmaceutics. 2023 Dec 29;16(1):60. DOI:10.3390/pharmaceutics16010060
[2] Trontinemab. IMGT/mAb-DB.
[3] Weber F, et al. Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. Cell Rep. 2018 Jan 2;22(1):149-162. DOI:10.1016/j.celrep.2017.12.019
[4] Roche H L. Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants with Prodromal or Mild to Moderate Alzheimer’s Disease[J]. ClinicalTrialsgov Identifier: NCT04639050, 2021, 2024.
Research Grade Trontinemab (DHC12508) Preparation Products And Raw materials
Raw materials
Preparation Products
Research Grade Trontinemab (DHC12508) Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
| Atagenix Laboratories | 027-87008169 17762441161 | info@atagenix.com | China | 9997 | 58 |
| Shanghai Amole Biotechnology Co., Ltd. | 13370042665 18916960931 | 2596183085@qq.com | China | 17234 | 58 |
View Latest Price from Research Grade Trontinemab (DHC12508) manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Trontinemab
2568868-35-7
|
$619.00 | 95.00% | 10g | TargetMol Chemicals Inc. |
-
- Trontinemab
2568868-35-7
- $619.00
- 95.00%
- TargetMol Chemicals Inc.
